ES8603949A1 - Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado - Google Patents

Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado

Info

Publication number
ES8603949A1
ES8603949A1 ES533767A ES533767A ES8603949A1 ES 8603949 A1 ES8603949 A1 ES 8603949A1 ES 533767 A ES533767 A ES 533767A ES 533767 A ES533767 A ES 533767A ES 8603949 A1 ES8603949 A1 ES 8603949A1
Authority
ES
Spain
Prior art keywords
cells
htnf
procedure
production
necrosis factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES533767A
Other languages
English (en)
Spanish (es)
Other versions
ES533767A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of ES8603949A1 publication Critical patent/ES8603949A1/es
Publication of ES533767A0 publication Critical patent/ES533767A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES533767A 1983-06-27 1984-06-27 Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado Granted ES533767A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50847283A 1983-06-27 1983-06-27

Publications (2)

Publication Number Publication Date
ES8603949A1 true ES8603949A1 (es) 1986-01-01
ES533767A0 ES533767A0 (es) 1986-01-01

Family

ID=24022900

Family Applications (2)

Application Number Title Priority Date Filing Date
ES533767A Granted ES533767A0 (es) 1983-06-27 1984-06-27 Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado
ES545258A Expired ES8608885A1 (es) 1983-06-27 1985-07-16 Procedimiento para distinguir celulas normales de malignas, en una mezcla de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES545258A Expired ES8608885A1 (es) 1983-06-27 1985-07-16 Procedimiento para distinguir celulas normales de malignas, en una mezcla de las mismas

Country Status (15)

Country Link
EP (1) EP0131789A3 (OSRAM)
JP (1) JPS6036420A (OSRAM)
KR (1) KR850000528A (OSRAM)
AU (1) AU587959B2 (OSRAM)
CA (1) CA1265444A (OSRAM)
DD (3) DD229713A5 (OSRAM)
DK (1) DK311984A (OSRAM)
ES (2) ES533767A0 (OSRAM)
FI (1) FI842560A7 (OSRAM)
GR (1) GR82260B (OSRAM)
HU (2) HU197358B (OSRAM)
NO (1) NO842572L (OSRAM)
NZ (1) NZ208648A (OSRAM)
PT (1) PT78773B (OSRAM)
ZA (1) ZA844377B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
JPS59141519A (ja) * 1983-01-31 1984-08-14 Otsuka Pharmaceut Co Ltd 制ガン作用を有する蛋白質
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS60243018A (ja) * 1984-05-17 1985-12-03 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US6686455B1 (en) 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
GR851626B (OSRAM) * 1984-07-05 1985-11-26 Genentech Inc
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
EP0313104A3 (en) * 1984-12-21 1989-07-12 Biogen, Inc. Purification, production and use of tumor necrosis factors
EP0205038A1 (en) * 1985-05-29 1986-12-17 Suntory Limited Polypeptide, process for preparing it, microorganism and pharmaceutical use
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
DE102012024749A1 (de) 2012-12-11 2014-06-26 Martin Röcken Tumorprävention und -therapie durch Induktion einer Tumorseneszenz

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
GR851626B (OSRAM) * 1984-07-05 1985-11-26 Genentech Inc

Also Published As

Publication number Publication date
NZ208648A (en) 1989-07-27
JPS6036420A (ja) 1985-02-25
NO842572L (no) 1984-12-28
EP0131789A3 (en) 1986-12-03
DD241271A5 (de) 1986-12-03
ES8608885A1 (es) 1986-07-16
DD241268A5 (de) 1986-12-03
FI842560A0 (fi) 1984-06-26
PT78773A (en) 1984-07-01
CA1265444A (en) 1990-02-06
AU587959B2 (en) 1989-09-07
GR82260B (OSRAM) 1984-12-13
ES545258A0 (es) 1986-07-16
KR850000528A (ko) 1985-02-27
EP0131789A2 (en) 1985-01-23
DD229713A5 (de) 1985-11-13
HUT34775A (en) 1985-04-28
ZA844377B (en) 1985-05-29
PT78773B (en) 1986-06-26
AU2933784A (en) 1985-01-03
DK311984D0 (da) 1984-06-26
HU201680B (en) 1990-12-28
DK311984A (da) 1984-12-28
HU197358B (en) 1989-03-28
FI842560L (fi) 1984-12-28
ES533767A0 (es) 1986-01-01
FI842560A7 (fi) 1984-12-28

Similar Documents

Publication Publication Date Title
ES8603949A1 (es) Procedimiento para la produccion de factor de necrosis tumoral humana (htnf) purificado
ES2147720T3 (es) Factor de celulas madre.
ES9000011A1 (es) Procedimiento para transformar un cultivo de celulas de modo que produzca activador de plasminogeno de tejido (t-pa) humano
ES8900017A1 (es) Procedimiento para la preparacion de dipeptidos de n,n-dialquil-guanidino.
ATE90345T1 (de) Bis-naphthalimide, ihre herstellung und verwendung.
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
ATE143811T1 (de) Herstellung und verwendung von il-6
NO834183L (no) Middel for kosmetisk hudpleie og fremgangsmaate ved fremstilling derav
ES8802493A1 (es) Procedimiento para la obtencion de amidas de acidos benzoheterociclilalcanoicos.
ES2102984T3 (es) Medios para el crecimiento de celulas y procedimiento para preparar los mismos.
ES452765A1 (es) Procedimiento para la preparacion de nuevos 2-tetrahidrofur-furil-6, 7-benzomorfanos disustituidos en 5,9-beta.
Burrows et al. STUDIES ON THE GROWTH OF CELLS. THE CULTIVATION OF BLADDER AND PROSTATIC TUMORS OUTSIDE THE BODY.
BG47038A3 (bg) МЕТОД ЗА ПОЛУЧАВАНЕ НА ПРОИЗВОДНИ НА 1Н,ЗН-ПИРОЛО/1,2-c/ТИАЗОЛА
UA6028A1 (uk) Спосіб одержання біологічно активної композиції
RO79168A (ro) Procedeu pentru prepararea unor derivati ai piriaidobenzazepinelor
SE8703210L (sv) Hudvardskompositioner med keratolytisk och antiinflammatorisk aktivitet
JPS6490199A (en) T cell growth factor derived from thymic interstitial cell and production thereof
BG32418A3 (en) Method for obtaining of amid derivatives of 1, 2, 3- thiadiazol- 5- carbonic acid
NO862710L (no) Forgrenet polykarbonat og fremgangsmaate for dets fremstilling.
SE8505286D0 (sv) Nytt lymfokin, monoklonala antikroppar specifika for lymfokinet och deras framstellning samt anvendningar
ES423289A1 (es) Procedimiento para preparar derivados de leurosina.
ATE46687T1 (de) Basisch substituierte phenylacetaldehyde, ihre herstellung und diese enthaltende arzneimittel.
ES8504794A1 (es) Un procedimiento para la preparacion de una quinazolina
IT1074829B (it) Procedimento per migliorare la macinabilita' di clinker di cemento e il potere di scorrimento del cemento
ES8900230A1 (es) Procedimiento para la obtencion de derivados de piridazo-(1,2-a)(1,2)diacepina